RWE in pharma: 5 minutes with…Faisal Mehmud


RWE in pharma_FM

In this ‘RWE in pharma’ interview series, we are putting various pharma experts in the spotlight and asking them to share their insight on how their industry has traditionally employed real-world evidence (RWE), how they envision this changing over the next few years and what their predictions of the impacts of the highly anticipated US FDA RWE Framework may be. Our expert for this instalment is Faisal Mehmud, Head of Global Risk Management within the Pharmacovigilance group at Bristol Myers Squibb (London, UK). Please could you introduce yourself, your organization(s) and tell us more about your role?  I am currently the Head...

To view this content, please register now for access

It's completely free